MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced a collaboration with iHope, a global ...
PacBio announced a key study published in the American Journal of Human Genetics by Radboud University Medical Center, showcasing the effectiveness of its HiFi long-read sequencing technology for ...
PacBio's Advanced Sequencing Solutions Enable Breakthrough in Understanding Rare Mendelian Condition
PacBio announced its involvement in a groundbreaking study published in Nature Genetics, which utilized its advanced sequencing technology to explore the genetic basis of a rare Mendelian condition in ...
MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PacBio (PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a significant advancement for global ...
StockStory.org on MSN
PACB Q4 deep dive: Consumables and clinical adoption drive growth as SparkNex launch nears
Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q4 CY2025 results , with sales up 13.8% year on year to $44.65 million. Its non-GAAP loss of $0.12 per share was 10.8% above ...
MENLO PARK, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- PacBio (PACB), a leading provider of high-quality, highly accurate long-read sequencing solutions, today announced that the National Institute on ...
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve ...
Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.
PacBio (PACB), a leading developer of high-quality, highly accurate genomic sequencing solutions, today announced the inclusion of the Onso short-read sequencing platform in the 10x Genomics ...
StockStory.org on MSN
PacBio (NASDAQ:PACB) reports strong Q4 CY2025
Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q4 CY2025 results , with sales up 13.8% year on ...
Pacific Biosciences of California (NASDAQ:PACB) reported fourth-quarter and full-year 2025 results that management said exceeded expectations, driven by record consumables revenue and stronger ...
PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year results: Gross margin, operating expenses, net income ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results